Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Adaptimmune Therapeutics (ADAP)
NASDAQ:ADAP
RESEARCH TOOLSreports
Adaptimmune Therapeutics (ADAP) Stock Price & Analysis
701 Followers
ADAP Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.42 - $2.05
Previous Close$1.13
Volume14.92M
Average Volume (3M)1.64M
Market Cap
$288.71M
Enterprise Value$168.75M
Total Cash (Recent Filing)$143.65M
Total Debt (Recent Filing)$23.69M
Price to Earnings (P/E)―
Beta1.99
Next Earnings
Aug 07, 2024EPS Estimate
-$0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.73
Shares Outstanding255,561,979
10 Day Avg. Volume2,587,125
30 Day Avg. Volume1,636,768
Standard Deviation0.48
R-Squared0.07
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)10.82
Price to Sales (P/S)4.79
Price to Cash Flow (P/CF)-2.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue9.19
Enterprise Value/Gross Profit2.80
Enterprise Value/Ebitda-1.10
Forecast
1Y Price Target
$2.69Price Target Upside138.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
Adaptimmune Therapeutics News
PremiumCompany Announcements
Adaptimmune Inks Lucrative Deal for Cancer Therapy Trial
PremiumCompany Announcements
Adaptimmune Secures $125M Loan for Corporate Growth and Product DevelopmentBulls Say, Bears Say
Bulls Say
Collaboration And Licensing AgreementsAdaptimmune's strategic collaboration with Galapagos could lead to significant financial gains through upfront payments, R&D funding, and potential milestone payments, strengthening its financial outlook and supporting its clinical trials.
Commercialization And Launch ReadinessAdaptimmune demonstrates strong commercial readiness for afami-cel with robust launch preparations, targeted focus on sarcoma centers of excellence, and financial arrangements in place to support operations well into the future.
Regulatory MilestonesThe upcoming PDUFA date for afami-cel in synovial sarcoma, combined with the FDA's current stance of not requiring an advisory committee meeting or a REMS program, suggests a favorable review process that could result in a timely approval.
Bears Say
Collaboration TerminationThe termination of the collaboration with Genentech will result in the removal of research payments and milestones from ADAP's financial model.
Financial PerformanceRevised revenue assumptions for afami-cel, lete-cel, and uza-cel indicate a more conservative approach to forecasting.
Safety ConcernsCommon adverse events reported for lete-cel include cytokine release syndrome and cytopenia, which may raise safety concerns.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ADAP FAQ
What was Adaptimmune Therapeutics’s price range in the past 12 months?
Adaptimmune Therapeutics lowest stock price was $0.42 and its highest was $2.05 in the past 12 months.
What is Adaptimmune Therapeutics’s market cap?
Currently, no data Available
When is Adaptimmune Therapeutics’s upcoming earnings report date?
Adaptimmune Therapeutics’s upcoming earnings report date is Aug 07, 2024 which is in 66 days.
How were Adaptimmune Therapeutics’s earnings last quarter?
Adaptimmune Therapeutics released its earnings results on May 15, 2024. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.153 by $0.123.
Is Adaptimmune Therapeutics overvalued?
According to Wall Street analysts Adaptimmune Therapeutics’s price is currently Undervalued.
Does Adaptimmune Therapeutics pay dividends?
Adaptimmune Therapeutics does not currently pay dividends.
What is Adaptimmune Therapeutics’s EPS estimate?
Adaptimmune Therapeutics’s EPS estimate is -$0.2.
How many shares outstanding does Adaptimmune Therapeutics have?
Adaptimmune Therapeutics has 255,561,980 shares outstanding.
What happened to Adaptimmune Therapeutics’s price movement after its last earnings report?
Adaptimmune Therapeutics reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.153. Following the earnings report the stock price went up 7.826%.
Which hedge fund is a major shareholder of Adaptimmune Therapeutics?
Among the largest hedge funds holding Adaptimmune Therapeutics’s share is Matrix Capital Management Company, LP. It holds Adaptimmune Therapeutics’s shares valued at 62M.
---
Adaptimmune Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.69 (138.05% Upside)
$2.69 (138.05% Upside)
Blogger Sentiment
Bullish
ADAP Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 182.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
10.78%
12-Months-Change
Fundamentals
Return on Equity
-302.27%
Trailing 12-Months
Asset Growth
-10.44%
Trailing 12-Months
Company Description
Adaptimmune Therapeutics
Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.
---
ADAP Earnings Call
Q1 2024
0:00 / 0:00
---
ADAP Stock 12 Month Forecast
Average Price Target
$2.69
▲(138.05% Upside)
Technical Analysis
Best Analysts Covering ADAP
1 Year
1 Year Success Rate
5/9 ratings generated profit
1 Year Average Return
+3.47%
reiterated a sell rating 17 days ago
Copying Peter Lawson's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of +3.47% per trade.
---